PIK3CA mutations in breast cancer are associated with poor outcome
Author:
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology
Link
http://link.springer.com/content/pdf/10.1007/s10549-005-9048-0.pdf
Reference15 articles.
1. Vivanco I, Sawyers CL, The phosphatidylinositol-3-Kinase AKT pathway in human cancer Nat Rev Cancer 2: 489–501, 2002
2. Sun M, Wang G, Paciga JE, Feldman RI, Yuan ZQ, Ma XL, Shelley SA, Jove R, Tsichlis PN, Nicosia SV, Cheng JQ, AKT1/PKBalpha kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells Am J Pathol 159: 431–437, 2001
3. Bellacosa A, de Feo D, Godwin AK, Bell DW, Cheng JQ, Altomare DA, Wan M, Dubeau L, Scambia G, Masciullo V, et al. Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas Int J Cancer 64: 280–285, 1995
4. Shayesteh L, Lu Y, Kuo WL, Baldocchi R, Godfrey T, Collins C, Pinkel D, Powell B, Mills GB, Gray JW, PIK3CA is implicated as an oncogene in ovarian cancer Nat Genet 21: 99–102, 1999
5. Saito M, Okamoto A, Kohno T, Takakura S, Shinozaki H, Isonishi S, Yasuhara T, Yoshimura T, Ohtake Y, Ochiai K, Yokota J, Tanaka T, Allelic imbalance and mutations of the PTEN gene in ovarian cancer Int J Cancer 85: 160–165, 2000
Cited by 175 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Characterizing the Tumor Microenvironment and Its Prognostic Impact in Breast Cancer;Cells;2024-09-10
2. PIK3CA mutational status in tissue and plasma as a prognostic biomarker in HR+/HER2− breast cancer;Cancer Medicine;2024-09
3. The PI3K/AKT/mTOR signaling pathway in breast cancer: Review of clinical trials and latest advances;Cell Biochemistry and Function;2024-04
4. Next-Generation Sequencing in Breast Cancer Patients: Real-World Data for Precision Medicine;Cancer Research and Treatment;2024-01-15
5. Predictive, preventive, and personalized medicine in breast cancer: targeting the PI3K pathway;Journal of Translational Medicine;2024-01-03
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3